Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report

Maro Ohanian, Christian Cable, Kathleen Halka Department of Hematology/Oncology, Scott &amp; White Healthcare and The Texas A&amp;M Health Science Center, College of Medicine, Temple, TX, USA Objective: To describe how maintenance eculizumab sustains improved renal function in severe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Halka K, Cable C, Ohanian M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4704dd7e62ae4571ad6fbff22e89e509
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4704dd7e62ae4571ad6fbff22e89e509
record_format	dspace
spelling	oai:doaj.org-article:4704dd7e62ae4571ad6fbff22e89e5092021-12-02T02:40:12ZReduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report1179-1438https://doaj.org/article/4704dd7e62ae4571ad6fbff22e89e5092011-11-01T00:00:00Zhttp://www.dovepress.com/reduced-dose-maintenance-eculizumab-in-atypical-hemolytic-uremic-syndr-a8576https://doaj.org/toc/1179-1438Maro Ohanian, Christian Cable, Kathleen Halka Department of Hematology/Oncology, Scott &amp; White Healthcare and The Texas A&amp;M Health Science Center, College of Medicine, Temple, TX, USA Objective: To describe how maintenance eculizumab sustains improved renal function in severe atypical hemolytic uremic syndrome (aHUS). Case report: A previously described 50-year-old woman with aHUS had a remarkable recovery with eculizumab, which safely reversed profound neurologic damage and eliminated the need for dialysis. Her recovery has been sustained on long-term eculizumab treatment. She initially received eculizumab 900 mg weekly for four doses. On week 5 she commenced maintenance therapy starting at 1200 mg every 2 weeks. Due to nausea and vomiting at that dose, the maintenance dosing was reduced to 600 mg weekly, beginning on dose seven. After receiving 600 mg weekly for nine doses, eculizumab was then reduced to 600 mg every 2 weeks, with continued improvement in renal function. This dosing is lower than the usual 1200 mg every 2 weeks described in the adult literature and used in current clinical trials of aHUS. Conclusion: Six months after the initial diagnosis, our patient continues to have improved renal function on maintenance doses of eculizumab as low as 600 mg every 2 weeks. Keywords: eculizumab, aHUS, thrombotic microangiopathy, atypical hemolytic uremic syndromeHalka KCable COhanian MDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2011, Iss default, Pp 45-50 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Halka K Cable C Ohanian M Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
description	Maro Ohanian, Christian Cable, Kathleen Halka Department of Hematology/Oncology, Scott &amp; White Healthcare and The Texas A&amp;M Health Science Center, College of Medicine, Temple, TX, USA Objective: To describe how maintenance eculizumab sustains improved renal function in severe atypical hemolytic uremic syndrome (aHUS). Case report: A previously described 50-year-old woman with aHUS had a remarkable recovery with eculizumab, which safely reversed profound neurologic damage and eliminated the need for dialysis. Her recovery has been sustained on long-term eculizumab treatment. She initially received eculizumab 900 mg weekly for four doses. On week 5 she commenced maintenance therapy starting at 1200 mg every 2 weeks. Due to nausea and vomiting at that dose, the maintenance dosing was reduced to 600 mg weekly, beginning on dose seven. After receiving 600 mg weekly for nine doses, eculizumab was then reduced to 600 mg every 2 weeks, with continued improvement in renal function. This dosing is lower than the usual 1200 mg every 2 weeks described in the adult literature and used in current clinical trials of aHUS. Conclusion: Six months after the initial diagnosis, our patient continues to have improved renal function on maintenance doses of eculizumab as low as 600 mg every 2 weeks. Keywords: eculizumab, aHUS, thrombotic microangiopathy, atypical hemolytic uremic syndrome
format	article
author	Halka K Cable C Ohanian M
author_facet	Halka K Cable C Ohanian M
author_sort	Halka K
title	Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
title_short	Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
title_full	Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
title_fullStr	Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
title_full_unstemmed	Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
title_sort	reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (ahus): an update on a previous case report
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/4704dd7e62ae4571ad6fbff22e89e509
work_keys_str_mv	AT halkak reduceddosemaintenanceeculizumabinatypicalhemolyticuremicsyndromeahusanupdateonapreviouscasereport AT cablec reduceddosemaintenanceeculizumabinatypicalhemolyticuremicsyndromeahusanupdateonapreviouscasereport AT ohanianm reduceddosemaintenanceeculizumabinatypicalhemolyticuremicsyndromeahusanupdateonapreviouscasereport
_version_	1718402281393618944

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report

Ejemplares similares